CLL Global Research Foundation Co Michael Keating

Filing Period

Jan 1, 2010 to Dec 31, 2010

Signed

May 3, 2011

Return Version

2010v3.2

Gross Receipts

$1,707,407

Mission

Major Activities

Activity 2

RESEARCH GRANTS: The CLL Global Research Foundation's primary activity is to accelerate research. The need is urgent to accelerate promising, untapped areas of research. CLLGRF provides grants through several mechanisms to fund novel, patient-oriented concepts. The intention is to fund the best science in the world. In particular, CLLGRF targets monoclonal antibodies, prognostic factors, vaccines & gene therapy, CLL survival pathway, genetics, molecular targets and drug development. A Scientific Advisory Board develops the research priorities and oversees the development and implementation of the submission, evaluation and funding process for grant application cycles. SAB members have extensive experience in treating CLL patients, developing new drugs and other tools and studying various aspects of the disease. The research grant section also allows support of postdoctoral fellows conducting a CLL specific project. In 2010, CLLGRF awarded $262,462* as research/individual grants. Applicants initially submit proposals for up to $100,000 in funding for one year. Applicants identify project milestones. Upon demonstration of sufficient progress, investigators will be considered for a second year of funding.*After a final reconciliation of expenses, recipients return any unused funds. In 2010, $2,900 was refunded, reducing the 2010 grant amount to $259,562.

Activity 3

GLOBAL COLLABORATION: Investigators from throughout the world have the opportunity to apply for CLLGRF's grants. CLLGRF believes strongly that global participation will be necessary to solve the CLL puzzle. CLLGRF is encouraging the establishment of collaborative working groups in a number of countries. Selected countries have been identified based on specific research capabilities and/or the ability to answer unique research questions. CLLGRF plans to support the initial infrastructure and research efforts in these countries. In previous years, initial funding was provided to Israel and Australia. No additional grants were expensed in 2010. However, upcoming progress reports will likely contain additional grant requests.

Filer

EIN

88-0517430